bioAffinity TechnologiesBIAF -1.48%44 Forward Dividend Yield % is 0.00% as of Jul. 11, 2026. GuruFocus rates BIAF with a GF Score™ of 44/100 and a GF Value™ of $4.26 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 63 Medical Diagnostics & Research companies, bioAffinity Technologies ranks worse than 1587300% on this metric.
As of today (2026-07-11), the Forward Annual Dividend Yield of bioAffinity Technologies is 0.00%.
As of today (2026-07-11), the Trailing Annual Dividend Yield of bioAffinity Technologies is 0.00%.
BIAF's Forward Dividend Yield % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.09 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
bioAffinity Technologies Forward Dividend Yield % Related Terms
BIAF vs NDRA, ISPC, ADVB: Forward Dividend Yield % Comparison
For the Diagnostics & Research subindustry, bioAffinity Technologies's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
bioAffinity Technologies Forward Dividend Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, bioAffinity Technologies's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where bioAffinity Technologies's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
bioAffinity Technologies (BIAF) has a Forward Dividend Yield % of 0.00% as of Jul. 11, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on bioAffinity Technologies and its competitors. According to the industry distribution chart, bioAffinity Technologies ranks #999999 out of 63 companies in the Medical Diagnostics & Research industry.
Is bioAffinity Technologies' Forward Dividend Yield % too high?
bioAffinity Technologies' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, bioAffinity Technologies ranks #999999 out of 63 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, bioAffinity Technologies has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does bioAffinity Technologies' Forward Dividend Yield % compare to NDRA and ISPC?
According to the Medical Diagnostics & Research industry distribution chart, bioAffinity Technologies ranks #999999 out of 63 companies for Forward Dividend Yield %. This places bioAffinity Technologies in the lower half of its industry. The industry median Forward Dividend Yield % is 2.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Diagnostics & Research company?
The median Forward Dividend Yield % among Medical Diagnostics & Research companies is 2.09, based on 63 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on bioAffinity Technologies and its competitors. For the Medical Diagnostics & Research industry, the median Forward Dividend Yield % is 2.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. bioAffinity Technologies's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is bioAffinity Technologies stock overvalued right now?
Based on GuruFocus' analysis, bioAffinity Technologies (BIAF) is currently considered Possible Value Trap. The stock's GF Value™ is $4.26, compared to a current price of $0.76 — trading 82.2% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. bioAffinity Technologies' overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For bioAffinity Technologies (BIAF), the current Forward Dividend Yield % is 0.00% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is bioAffinity Technologies (BIAF) Overvalued in 2026?
Based on GuruFocus' analysis, bioAffinity Technologies stock appears to be undervalued.
The current stock price of $0.76 is trading 82.2% below its estimated GF Value™ of $4.26.
GuruFocus considers bioAffinity Technologies to be Possible Value Trap.
Key valuation signals for BIAF:
Forward Dividend Yield %: 0.00%
GF Value™: $4.26 vs. price of $0.76 (82.2% below fair value)
No single metric tells the full story. See the BIAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
44GF Score
Get the complete analysis for BIAF
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIAF has been successfully added to your 